Are there salivary gland size changes with repetitive onabotulinum toxin A (OBTXA) injections for sialorrhea treatment in children, and do they correlate with clinical outcomes?
Background: OBTXA injection is a well-established option for management of pediatric drooling (sialorrhea), which is considered pathological after four years of age. Several management modalities exist, including anticholinergic drugs, rehabilitation with oral and motor therapy, surgical intervention, and local irradiation of salivary glands. The long-term effect of repetitive OBTXA injection in pediatric salivary glands is still not well known, however.
Explore this issue:March 2016
Study design: Case control study conducted between October 2013 and February 2014 of 60 patients (22 treatment, 38 control) with a mean age of 7 years.
Setting: Montreal Children’s Hospital, McGill University Health Center, Montreal, Quebec, Canada.